Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS.

Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS.

Successful radiosensitization requires that tumor cells become more radiosensitive without causing an equivalent reduction in the survival of cells of the surrounding normal tissues. Since tumor cell radiosensitivity can be influenced by RAS oncogene activation, we have hypothesized that inhibition...

Ausführliche Beschreibung

Bibliographische Detailangaben
Hauptverfasser:	Cohen-Jonathan, E, Muschel, R, Gillies McKenna, W, Evans, S, Cerniglia, G, Mick, R, Kusewitt, D, Sebti, S, Hamilton, A, Oliff, A, Kohl, N, Gibbs, J, Bernhard, E
Format:	Conference item
Veröffentlicht:	2000

Ähnliche Einträge

Farnesyltransferase inhibitors.
von: Hahn, S, et al.
Veröffentlicht: (2001)

Farnesyltransferase inhibitors as radiation sensitizers.
von: Mckenna, W, et al.
Veröffentlicht: (2002)

The farnesyltransferase inhibitor L744,832 reduces hypoxia in tumors expressing activated H-ras.
von: Cohen-Jonathan, E, et al.
Veröffentlicht: (2001)

Farnesyltransferase inhibitors as radiation sensitizers.
von: Brunner, T, et al.
Veröffentlicht: (2003)

Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations.
von: Brunner, T, et al.
Veröffentlicht: (2003)

Farnesyltransferase inhibitors as radiation sensitizers
von: Mckenna, W
Veröffentlicht: (2005)

HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo.
von: Gupta, A, et al.
Veröffentlicht: (2005)

The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma.
von: Cesca, M, et al.
Veröffentlicht: (2009)

Assessment Of Antitumor Activity Of Standardized Polyalthia Longifolia Leaf Extract In Hela Cell Tumor Xenograft Mouse Model
von: Braganza, Cilwyn Shalitha
Veröffentlicht: (2022)

Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice.
von: Balasis, M, et al.
Veröffentlicht: (2011)

Structural basis for binding and selectivity of antimalarial and anticancer ethylenediamine inhibitors to protein farnesyltransferase.
von: Hast, M, et al.
Veröffentlicht: (2009)

Modifying radiosensitivity in tumors: Targeting the Ras-PI-3 kinase pathway.
von: Muschel, R, et al.
Veröffentlicht: (2001)

CELL-MEDIATED RESPONSES TO TUMOR XENOGRAFTS IN MICE
von: Simpson, E, et al.
Veröffentlicht: (1972)

Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts
von: Kumar, K, et al.
Veröffentlicht: (2013)

Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts.
von: Kumar, K, et al.
Veröffentlicht: (2013)

Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors.
von: Goriely, A, et al.
Veröffentlicht: (2009)

Lymphocyte-dependent antibody in a tumor xenograft system.
von: Simpson, E, et al.
Veröffentlicht: (1973)

C-Raf-1 protein kinase is not essential for Ras transformation of mouse embryo fibroblasts.
von: Gupta, A, et al.
Veröffentlicht: (2003)

Structure-based design and synthesis of potent, ethylenediamine-based, mammalian farnesyltransferase inhibitors as anticancer agents.
von: Fletcher, S, et al.
Veröffentlicht: (2010)

Down-regulation of Akt signaling with HIV-1 protease inhibitors
von: Gupta, A, et al.
Veröffentlicht: (2005)

Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines.
von: Bernhard, E, et al.
Veröffentlicht: (2000)

A Phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancer.
von: Hahn, S, et al.
Veröffentlicht: (2002)

A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer.
von: Martin, N, et al.
Veröffentlicht: (2004)

Potent, Plasmodium-selective farnesyltransferase inhibitors that arrest the growth of malaria parasites: structure-activity relationships of ethylenediamine-analogue scaffolds and homology model validation.
von: Fletcher, S, et al.
Veröffentlicht: (2008)

Contributions of intrinsic mutation rate and selfish selection to levels of de novo HRAS mutations in the paternal germline.
von: Giannoulatou, E, et al.
Veröffentlicht: (2013)

A phase I trial of the farnesyltransferase and geranylgeranyltransferase-I inhibitor L-778,123 (L-778) and radiotherapy for locally advanced pancreatic cancer.
von: Martin, N, et al.
Veröffentlicht: (2004)

Exploring Protoheme IX Farnesyltransferase as an Antimalarial Drug Target
von: Edelen, Samantha Leigh
Veröffentlicht: (2022)

The Effect of Advanced Paternal Age on Genetic Risks Is Mediated through Dysregulation of HRAS Signalling in the Testis.
von: Goriely, A, et al.
Veröffentlicht: (2011)

The injury response to DNA damage in live tumor cells promotes antitumor immunity
von: Sriram, Ganapathy, et al.
Veröffentlicht: (2023)

Efficacy, pharmacokinetics, and metabolism of tetrahydroquinoline inhibitors of Plasmodium falciparum protein farnesyltransferase.
von: Van Voorhis, W, et al.
Veröffentlicht: (2007)

Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002.
von: Gupta, A, et al.
Veröffentlicht: (2003)

Targeting tumor cells by enhancing radiation sensitivity.
von: Mckenna, W, et al.
Veröffentlicht: (2003)

Modulation of the tumor microvasculature by phosphoinositide-3 kinase inhibition increases doxorubicin delivery in vivo.
von: Qayum, N, et al.
Veröffentlicht: (2012)

Tumor vascular changes mediated by inhibition of oncogenic signaling.
von: Qayum, N, et al.
Veröffentlicht: (2009)

Antitumor effects and normal-tissue toxicity of 111In-nuclear localization sequence-trastuzumab in athymic mice bearing HER-positive human breast cancer xenografts.
von: Costantini, D, et al.
Veröffentlicht: (2010)

The Ras radiation resistance pathway.
von: Gupta, A, et al.
Veröffentlicht: (2001)

Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature.
von: Fokas, E, et al.
Veröffentlicht: (2012)

Phosphorylation of glycogen sythase kinase-3 beta does not contribute to radiation resistance in two cell lines with activation of the Akt pathway
von: Gupta, A, et al.
Veröffentlicht: (2004)

The impact of tumor microenvironment on cancer treatment and its modulation by direct and indirect antivascular strategies.
von: Fokas, E, et al.
Veröffentlicht: (2012)

The impact of tumor microenvironment on cancer treatment and its modulation by direct and indirect antivascular strategies
von: Fokas, E, et al.
Veröffentlicht: (2012)